MX356797B - Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro. - Google Patents

Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro.

Info

Publication number
MX356797B
MX356797B MX2014005378A MX2014005378A MX356797B MX 356797 B MX356797 B MX 356797B MX 2014005378 A MX2014005378 A MX 2014005378A MX 2014005378 A MX2014005378 A MX 2014005378A MX 356797 B MX356797 B MX 356797B
Authority
MX
Mexico
Prior art keywords
alpha
synuclein
brain
diagnose
elevated level
Prior art date
Application number
MX2014005378A
Other languages
English (en)
Spanish (es)
Other versions
MX2014005378A (es
Inventor
Weihofen Andreas
Grimm Jan
Engber Thomas
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MX2014005378A publication Critical patent/MX2014005378A/es
Publication of MX356797B publication Critical patent/MX356797B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/385—Congenital anomalies
    • G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
MX2014005378A 2011-11-02 2012-10-29 Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro. MX356797B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161554924P 2011-11-02 2011-11-02
PCT/US2012/062430 WO2013066818A1 (en) 2011-11-02 2012-10-29 USE OF AN ANTI-α-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF α-SYNUCLEIN IN THE BRAIN

Publications (2)

Publication Number Publication Date
MX2014005378A MX2014005378A (es) 2015-01-19
MX356797B true MX356797B (es) 2018-06-14

Family

ID=48192661

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014005378A MX356797B (es) 2011-11-02 2012-10-29 Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro.

Country Status (13)

Country Link
US (3) US20140295465A1 (enExample)
EP (1) EP2773957B1 (enExample)
JP (1) JP6263473B2 (enExample)
KR (1) KR102036938B1 (enExample)
CN (2) CN104040342A (enExample)
AU (1) AU2012332814B2 (enExample)
BR (1) BR112014010664A2 (enExample)
CA (1) CA2854131C (enExample)
EA (1) EA034213B1 (enExample)
IL (1) IL232373B (enExample)
MX (1) MX356797B (enExample)
WO (1) WO2013066818A1 (enExample)
ZA (1) ZA201403879B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
JP6273338B1 (ja) * 2016-12-05 2018-01-31 磁量生技股▲ふん▼有限公司 パーキンソン病からパーキンソン病認知症を特定する方法
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EP3725806A4 (en) 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
WO2020009482A1 (ko) * 2018-07-03 2020-01-09 에이비엘바이오 주식회사 항 알파-시누클레인 항체 및 그 용도
EP3629021A1 (en) * 2018-09-26 2020-04-01 Euroimmun Medizinische Labordiagnostika AG Diagnosis of a neuroautoimmune disease
KR102252879B1 (ko) * 2019-11-15 2021-05-17 성균관대학교산학협력단 혈장 내 aimp2를 이용한 파킨슨 질환의 진단 방법, 이를 위한 조성물 및 이를 포함하는 키트

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
AU3117799A (en) * 1998-03-30 1999-10-18 Trustees Of The University Of Pennsylvania, The Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
WO2002004482A1 (en) * 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
WO2007011907A2 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
CN101308144A (zh) * 2007-05-16 2008-11-19 首都医科大学宣武医院 检测受试者体液内疾病相关蛋白聚合能力的方法
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
CN101692092B (zh) * 2009-09-24 2013-04-10 首都医科大学宣武医院 定量检测人血清中自体α-突触核蛋白抗体的方法

Also Published As

Publication number Publication date
AU2012332814A1 (en) 2014-06-12
EA034213B1 (ru) 2020-01-17
EA201490883A1 (ru) 2014-10-30
ZA201403879B (en) 2018-11-28
KR102036938B1 (ko) 2019-10-25
IL232373B (en) 2018-08-30
HK1201585A1 (en) 2015-09-04
JP6263473B2 (ja) 2018-01-31
KR20140095074A (ko) 2014-07-31
US20190094245A1 (en) 2019-03-28
EP2773957A1 (en) 2014-09-10
CA2854131C (en) 2020-07-07
AU2012332814B2 (en) 2017-12-14
EP2773957A4 (en) 2015-06-24
US20140295465A1 (en) 2014-10-02
IL232373A0 (en) 2014-06-30
CN107091931A (zh) 2017-08-25
EP2773957B1 (en) 2017-11-29
JP2014533357A (ja) 2014-12-11
MX2014005378A (es) 2015-01-19
WO2013066818A1 (en) 2013-05-10
US20180011112A1 (en) 2018-01-11
CA2854131A1 (en) 2013-05-10
NZ625217A (en) 2016-07-29
BR112014010664A2 (pt) 2017-04-25
CN104040342A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
MX356797B (es) Uso de anticuerpo anti-alfa-sinucleina para diagnosticar nivel elevado de alfa-sinucleina en el cerebro.
CY1122278T1 (el) Αντι il-36r αντισωματα
CR20130359A (es) Anticuerpos del cea
MX353958B (es) Proteinas de union al antigeno cd27l.
DK3378535T3 (da) Humanserede antistoffer, der genkender alpha-synuklein
PH12014502406B1 (en) Anti-il-23p19 antibodies
MA34091B1 (fr) Anticorps anti-cd40
PH12014501164A1 (en) Anti-cd98 antibodies and methods of use thereof
CR20140441A (es) Anticuerpos anti-lgr5 e inmunoconjugados
EA201692042A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
IL231996B (en) Virtual reality for movement disorder diagnosis and/or treatment
PH12014502399B1 (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
IN2012DN02521A (enExample)
ZA201304334B (en) Methods for diagnosing and treating eye-length related disorders
MX356933B (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
NZ716643A (en) Methods for predicting the risk of having a cardiovascular event and for monitoring the treatment of a cardiovascular event
WO2013049152A3 (en) Methods for evaluating lung cancer status
MX368474B (es) Uso de benralizumab para mejorar síntomas de asma.
GB201103780D0 (en) Treatment for ige-mediated disease
MX2016006584A (es) Métodos y composiciones para tratar los depósitos de amiloide.
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2012135657A3 (en) Compositions and methods for diagnosis, preventing and treating intracranial aneurysms
FI20116047L (fi) Menetelmä terveyskortin hallinnoimiseksi
MX2014005196A (es) Modelo de citotoxidad celular dependiente de anticuerpos (adcc) in vivo.

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: HENKEL IP & HOLDING GMBH

FG Grant or registration